1
|
Lundon DJ, Boland A, Prencipe M, Hurley G, O'Neill A, Kay E, Aherne ST, Doolan P, Madden SF, Clynes M, Morrissey C, Fitzpatrick JM, Watson RW. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation. BMC Cancer 2017; 17:163. [PMID: 28249598 PMCID: PMC5333466 DOI: 10.1186/s12885-017-3100-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Accepted: 02/01/2017] [Indexed: 02/06/2023] Open
Abstract
Background Docetaxel based therapy is one of the first line chemotherapeutic agents for the treatment of metastatic castrate-resistant prostate cancer. However, one of the major obstacles in the treatment of these patients is docetaxel-resistance. Defining the mechanisms of resistance so as to inform subsequent treatment options and combinations represents a challenge for clinicians and scientists. Previous work by our group has shown complex changes in pro and anti-apoptotic proteins in the development of resistance to docetaxel. Targeting these changes individually does not significantly impact on the resistant phenotype but understanding the central signalling pathways and transcription factors (TFs) which control these could represent a more appropriate therapeutic targeting approach. Methods Using a number of docetaxel-resistant sublines of PC-3 cells, we have undertaken a transcriptomic analysis by expression microarray using the Affymetrix Human Gene 1.0 ST Array and in conjunction with bioinformatic analyses undertook to predict dysregulated TFs in docetaxel resistant prostate cancer. The clinical significance of this prediction was ascertained by performing immunohistochemical (IHC) analysis of an identified TF (SRF) in the metastatic sites from men who died of advanced CRPC. Investigation of the functional role of SRF was examined by manipulating SRF using SiRNA in a docetaxel-resistant PC-3 cell line model. Results The transcription factors identified include serum response factor (SRF), nuclear factor kappa-B (NFκB), heat shock factor protein 1 (HSF1), testicular receptor 2 & 4 (TR2 &4), vitamin-D and retinoid x receptor (VDR-RXR) and oestrogen-receptor 1 (ESR1), which are predicted to be responsible for the differential gene expression observed in docetaxel-resistance. IHC analysis to quantify nuclear expression of the identified TF SRF correlates with both survival from date of bone metastasis (p = 0.003), survival from androgen independence (p = 0.00002), and overall survival from prostate cancer (p = 0.0044). Functional knockdown of SRF by siRNA demonstrated a reversal of apoptotic resistance to docetaxel treatment in the docetaxel-resistant PC-3 cell line model. Conclusions Our results suggest that SRF could aid in treatment stratification of prostate cancer, and may also represent a therapeutic target in the treatment of men afflicted with advanced prostate cancer. Electronic supplementary material The online version of this article (doi:10.1186/s12885-017-3100-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- D J Lundon
- UCD School of Medicine, Conway Institute of Biomedical and Biomolecular Sciences, University College Dublin, Belfield, Dublin, Dublin 4, Ireland.
| | - A Boland
- UCD School of Mathematical Sciences and Insight, University College Dublin, Belfield, Dublin, Dublin 4, Ireland
| | - M Prencipe
- UCD School of Medicine, Conway Institute of Biomedical and Biomolecular Sciences, University College Dublin, Belfield, Dublin, Dublin 4, Ireland
| | - G Hurley
- UCD School of Biomolecular and Biomedical Science, University College Dublin, Belfield, Dublin, Dublin 4, Ireland
| | - A O'Neill
- UCD School of Medicine, Conway Institute of Biomedical and Biomolecular Sciences, University College Dublin, Belfield, Dublin, Dublin 4, Ireland
| | - E Kay
- Department of Pathology, Beaumont Hospital & Royal College of Surgeons in Ireland, Dublin, Ireland
| | - S T Aherne
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland Non-US/Non-Canadian, Ireland
| | - P Doolan
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland Non-US/Non-Canadian, Ireland
| | - S F Madden
- UCD School of Biomolecular and Biomedical Science, University College Dublin, Belfield, Dublin, Dublin 4, Ireland
| | - M Clynes
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland Non-US/Non-Canadian, Ireland
| | - C Morrissey
- Department of Urology, University of Washington, Seattle, WA, USA
| | - J M Fitzpatrick
- UCD School of Medicine, Conway Institute of Biomedical and Biomolecular Sciences, University College Dublin, Belfield, Dublin, Dublin 4, Ireland
| | - R W Watson
- UCD School of Medicine, Conway Institute of Biomedical and Biomolecular Sciences, University College Dublin, Belfield, Dublin, Dublin 4, Ireland
| |
Collapse
|
2
|
Hennessy E, Rakovac Tisdall A, Murphy N, Carroll A, O'Gorman D, Breen L, Clarke C, Clynes M, Dowling P, Sreenan S. Elevated 12-hydroxyeicosatetraenoic acid (12-HETE) levels in serum of individuals with newly diagnosed Type 1 diabetes. Diabet Med 2017; 34:292-294. [PMID: 27353008 DOI: 10.1111/dme.13177] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/27/2016] [Indexed: 11/29/2022]
Affiliation(s)
- E Hennessy
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
- 3U Diabetes, Dublin City University, Royal College of Surgeons in Ireland, Maynooth University, Dublin, Ireland
| | - A Rakovac Tisdall
- 3U Diabetes, Dublin City University, Royal College of Surgeons in Ireland, Maynooth University, Dublin, Ireland
- Connolly Hospital Blanchardstown, Dublin, Ireland
| | - N Murphy
- Children's University Hospital, Dublin, Ireland
| | - A Carroll
- Children's University Hospital, Dublin, Ireland
| | - D O'Gorman
- 3U Diabetes, Dublin City University, Royal College of Surgeons in Ireland, Maynooth University, Dublin, Ireland
- Centre for Preventive Medicine, School of Health and Human Performance, Dublin City University, Dublin, Ireland
| | - L Breen
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
- 3U Diabetes, Dublin City University, Royal College of Surgeons in Ireland, Maynooth University, Dublin, Ireland
- Centre for Preventive Medicine, School of Health and Human Performance, Dublin City University, Dublin, Ireland
| | - C Clarke
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
- 3U Diabetes, Dublin City University, Royal College of Surgeons in Ireland, Maynooth University, Dublin, Ireland
| | - M Clynes
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
- 3U Diabetes, Dublin City University, Royal College of Surgeons in Ireland, Maynooth University, Dublin, Ireland
| | - P Dowling
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
- 3U Diabetes, Dublin City University, Royal College of Surgeons in Ireland, Maynooth University, Dublin, Ireland
- Department of Biology, Maynooth University, Dublin, Ireland
| | - S Sreenan
- 3U Diabetes, Dublin City University, Royal College of Surgeons in Ireland, Maynooth University, Dublin, Ireland
- Connolly Hospital Blanchardstown, Dublin, Ireland
| |
Collapse
|
3
|
Litwic AE, Clynes M, Denison HJ, Jameson KA, Edwards MH, Sayer AA, Taylor P, Cooper C, Dennison EM. Non-invasive Assessment of Lower Limb Geometry and Strength Using Hip Structural Analysis and Peripheral Quantitative Computed Tomography: A Population-Based Comparison. Calcif Tissue Int 2016; 98:158-64. [PMID: 26590812 PMCID: PMC4723614 DOI: 10.1007/s00223-015-0081-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2015] [Accepted: 11/06/2015] [Indexed: 11/27/2022]
Abstract
Hip fracture is the most significant complication of osteoporosis in terms of mortality, long-term disability and decreased quality of life. In the recent years, different techniques have been developed to assess lower limb strength and ultimately fracture risk. Here we examine relationships between two measures of lower limb bone geometry and strength; proximal femoral geometry and tibial peripheral quantitative computed tomography. We studied a sample of 431 women and 488 men aged in the range 59-71 years. The hip structural analysis (HSA) programme was employed to measure the structural geometry of the left hip for each DXA scan obtained using a Hologic QDR 4500 instrument while pQCT measurements of the tibia were obtained using a Stratec 2000 instrument in the same population. We observed strong sex differences in proximal femoral geometry at the narrow neck, intertrochanteric and femoral shaft regions. There were significant (p < 0.001) associations between pQCT-derived measures of bone geometry (tibial width; endocortical diameter and cortical thickness) and bone strength (strength strain index) with each corresponding HSA variable (all p < 0.001) in both men and women. These results demonstrate strong correlations between two different methods of assessment of lower limb bone strength: HSA and pQCT. Validation in prospective cohorts to study associations of each with incident fracture is now indicated.
Collapse
Affiliation(s)
- A E Litwic
- MRC Lifecourse Epidemiology Unit, (University of Southampton) Southampton General Hospital, Southampton, SO16 6YD, UK
| | - M Clynes
- MRC Lifecourse Epidemiology Unit, (University of Southampton) Southampton General Hospital, Southampton, SO16 6YD, UK
| | - H J Denison
- MRC Lifecourse Epidemiology Unit, (University of Southampton) Southampton General Hospital, Southampton, SO16 6YD, UK
| | - K A Jameson
- MRC Lifecourse Epidemiology Unit, (University of Southampton) Southampton General Hospital, Southampton, SO16 6YD, UK
| | - M H Edwards
- MRC Lifecourse Epidemiology Unit, (University of Southampton) Southampton General Hospital, Southampton, SO16 6YD, UK
| | - A A Sayer
- MRC Lifecourse Epidemiology Unit, (University of Southampton) Southampton General Hospital, Southampton, SO16 6YD, UK
- Institute for Ageing and Institute of Health & Society, Newcastle University, Callaghan, Australia
| | - P Taylor
- MRC Lifecourse Epidemiology Unit, (University of Southampton) Southampton General Hospital, Southampton, SO16 6YD, UK
| | - C Cooper
- MRC Lifecourse Epidemiology Unit, (University of Southampton) Southampton General Hospital, Southampton, SO16 6YD, UK
- NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK
| | - E M Dennison
- MRC Lifecourse Epidemiology Unit, (University of Southampton) Southampton General Hospital, Southampton, SO16 6YD, UK.
- Victoria University of Wellington, Wellington, New Zealand.
| |
Collapse
|
4
|
McMahon FW, Gallagher C, O'Reilly N, Clynes M, O'Sullivan F, Kavanagh K. Exposure of a Corneal Epithelial Cell Line (hTCEpi) to Demodex-Associated Bacillus Proteins Results in an Inflammatory Response. Invest Ophthalmol Vis Sci 2014; 55:7019-28. [DOI: 10.1167/iovs.14-15018] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
5
|
Madden S, Gaule P, Clarke C, Aherne ST, O'Donovan N, Clynes M, Crown J, Gallagher WM. Abstract P3-04-12: BreastMark: An integrated approach to mining publically available Transcriptomic Datasets relating to Breast Cancer Outcome. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-04-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer is a complex heterogeneous disease for which a substantial resource of transcriptomic data is available. Indeed, gene expression data have facilitated the division of breast cancer into, at least, five molecular subtypes, Luminal A, Luminal B, Her2, Normal-like and Basal. Once identified, breast cancer subtypes can inform clinical decisions surrounding patient treatment and prognosis. It is important to identify patients at risk of developing aggressive disease so as to tailor the level of clinical intervention.
Methods: We have developed a user-friendly web-based system to allow the identification and evaluation of genes that are significantly associated with disease progression and survival for breast cancer in general and also with respect to molecular subtype. The underlying algorithm combines gene expression data from multiple DNA microarray experiments and detailed clinical data to correlate outcome with gene expression levels. This algorithm integrates gene expression and survival data from 21 datasets on 10 different microarray platforms corresponding to 20,017 gene sequences across 3,519 samples.
Results: We demonstrate the robustness of our approach in comparison to two commercially available prognostic tests in breast cancer. Our algorithm complements these prognostic tests and is consistent with their findings. In addition, BreastMark can act as a powerful reductionist approach to these more complex gene signatures, eliminating superfluous genes, potentially reducing the complexity and cost of these multi-index assays. We also applied the algorithm to examine expression of 58 receptor tyrosine kinases in the basal-like subtype of breast cancer, identifying seven receptor tyrosine kinases associated with poor disease-free survival and/or overall survival in this subtype (EPHA5, FGFR1, FGFR3, VEGFR1, PDGFRβ, ROS, TIE1). A web application for using this algorithm is currently available at http://glados.ucd.ie/BreastMark/index.html.
Conclusions: BreastMark is a useful tool for examining putative prognostic markers at the RNA level in breast cancer. The value of this tool will be in the preliminary assessment of putative biomarkers in breast cancer as a whole and within its molecular subtypes. It will be of particular use to clinical and academic research groups with limited bioinformatics facilities.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-04-12.
Collapse
Affiliation(s)
- S Madden
- Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland; University College Dublin, Dublin 9, Ireland
| | - P Gaule
- Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland; University College Dublin, Dublin 9, Ireland
| | - C Clarke
- Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland; University College Dublin, Dublin 9, Ireland
| | - ST Aherne
- Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland; University College Dublin, Dublin 9, Ireland
| | - N O'Donovan
- Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland; University College Dublin, Dublin 9, Ireland
| | - M Clynes
- Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland; University College Dublin, Dublin 9, Ireland
| | - J Crown
- Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland; University College Dublin, Dublin 9, Ireland
| | - WM Gallagher
- Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland; University College Dublin, Dublin 9, Ireland
| |
Collapse
|
6
|
Keenan J, Dooley M, Pearson D, Clynes M. Recombinant Human Albumin in Cell Culture: Evaluation of Growth-Promoting Potential for NRK and SCC-9 Cells In Vitro. Cytotechnology 2012; 24:243-52. [PMID: 22358768 DOI: 10.1023/a:1007916930200] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Serum-derived albumin has for a long time been used in cell culture media, but the exact role of albumin and/or impurities bound to albumin has not been precisely defined. In this study, recombinant human albumin was evaluated for its growth-promoting activity on two cell lines, NRK and SCC-9. For NRK cells, the recombinant human albumin was found to exert an inhibitory effect. The fact that fatty acid free HSA was also inhibitory while HSA fraction V was stimulatory suggested a role for fatty acids or some other bound moieties in growth stimulation by HSA fraction V. Addition of oleic acid, cholesterol, phosphatidylcholine, phosphatidylserine or a combination of these lipids, however, did not significantly improve the growth stimulating activity of either fatty acid free HSA or the recombinant human albumin. For SCC-9 cells, both recombinant human albumin and fatty acid free HSA showed slight stimulation (although they were not as active as HSA fraction V), suggesting that in some cell systems, the albumin molecule per se may promote cell growth and survival.
Collapse
|
7
|
Byrne D, Daly C, Nicamhlaoibh R, Howlett A, Scanlon K, Clynes M. Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance. Cytotechnology 2012; 27:113-36. [PMID: 19002787 DOI: 10.1023/a:1008052401952] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Chemotherapy can cure a number of human cancers but resistance (either intrinsic or acquired) remains a significant problem in many patients and in many types of solid tumour. Combination chemotherapy (using drugs with different cellular targets/mechanisms) was introduced in order to kill cells which had developed resistance to a specific drug, and to allow delivery of a greater total dose of anti-cancer chemicals by combining drugs with different side-effects (Pratt et al., 1994). Nearly all anti-cancer drugs kill tumour cells by activating an endogenous bio-chemical pathway for cell suicide, known as programmed cell death or apoptosis.
Collapse
Affiliation(s)
- D Byrne
- National Cell and Tissue Culture Centre, Dublin City University, Glasnevin, Dublin 9, Ireland
| | | | | | | | | | | |
Collapse
|
8
|
Rogers A, Smith MJ, Doolan P, Clarke C, Clynes M, Murphy JF, McDermott A, Swan N, Crotty P, Ridgway PF, Conlon KC. Invasive markers identified by gene expression profiling in pancreatic cancer. Pancreatology 2011; 12:130-40. [PMID: 22487523 DOI: 10.1016/j.pan.2011.12.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Molecular profiling has proven utility as a diagnostic and predictive tool in clinical oncology. However, a clinically relevant gene expression profile in pancreatic cancer remains elusive. METHODS Primary and metastatic pancreatic cancer cell lines (BxPC-3 and AsPC-1), were stimulated with phorbol-12-myristate 13-acetate (PMA), a known inducer of cell invasion. Affymetrix gene expression microarray analysis was performed, comparing gene expression to unstimulated controls. Differential expression was identified using ArrayAssist, and confirmed using quantitative real-time PCR. Bioinformatic analysis was performed using Pathway Studio and GOstat. The derived gene expression was further validated in fresh frozen pancreatic tumour samples. The ability of the derived 3 gene expression markersto differentiate between pancreatic adenocarcinoma (PDAC) and other neoplasms, and its association with clinicopathological variables was examined. RESULTS PMA-induced significant changes in cell line gene expression, from which distinctive 3 potential invasive markers were derived. Expression of these genes, uPA, MMP-1 and IL1-R1 was confirmed in human pancreatic tumours, and was found to differentiate PDAC from other pancreatic neoplasms. The expression of IL1-R1 in PDAC is a novel finding. We found that the expression of MMP-1 was associated with high-grade PDAC (p = 0.035, Wilcoxon rank sum). CONCLUSION We have identified three potential invasive markers, uPA, MMP-1 and IL1-R1, whose gene expression may differentiate PDAC from other pancreatic neoplasms, and potentially reflect a more invasive phenotype.
Collapse
Affiliation(s)
- A Rogers
- Department of Surgery, Trinity College Dublin, The Adelaide and Meath Hospital Incorporating the National Children's Hospital, Tallaght, Dublin 24, Ireland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Ammoun S, Zhou L, Barczyk M, Hilton D, Hafizi S, Hanemann C, Lehnus KS, Donovan LK, Pilkington GJ, An Q, Anderson IA, Thomson S, Bailey M, Lekka E, Law J, Davis C, Banfill K, Loughrey C, Hatfield P, Bax D, Elliott R, Bishop R, Taylor K, Marshall L, Gaspar N, Viana-Pereira M, Reis R, Renshaw J, Ashworth A, Lord C, Jones C, Bellamy C, Shaw L, Alder J, Shorrocks A, Lea R, Birks S, Burnet M, Pilkington G, Bruch JD, Ho J, Watts C, Price SJ, Camp S, Apostolopoulos V, Mehta A, Roncaroli F, Nandi D, Clark B, Mackinnon M, MacLeod N, Stewart W, Chalmers A, Cole A, Hanna G, Bailie K, Conkey D, Harney J, Darlow C, Chapman S, Mohsen L, Price S, Donovan L, Birks S, Pilkington G, Dyer H, Lord H, Fletcher K, das Nair R, MacNiven J, Basu S, Byrne P, Glancz L, Critchley G, Grech-Sollars M, Saunders D, Phipps K, Clayden J, Clark C, Greco A, Acquati S, Marino S, Hammouche S, Wilkins SP, Smith T, Brodbelt A, Hammouche S, Clark S, Wong AHL, Eldridge P, Farah JO, Ho J, Bruch J, Watts C, Price S, Lamb G, Smith S, James A, Glegg M, Jeffcote T, Boulos S, Robbins P, Knuckey N, Banigo A, Brodbelt AR, Jenkinson MD, Jeyapalan JN, Mumin MA, Forshew T, Lawson AR, Tatevossian RG, Jacques TS, Sheer D, Kilday J, Wright K, Leavy S, Lowe J, Schwalbe E, Clifford S, Gilbertson R, Coyle B, Grundy R, Kinsella P, Clynes M, Amberger-Murphy V, Barron N, Lambert SR, Jones D, Pearson D, Ichimura I, Collins V, Steele L, Sinha P, Chumas P, Tyler J, Ogawa D, Chiocca E, DeLay M, Bronisz A, Nowicki M, Godlewski J, Lawler S, Lee MK, Javadpour M, Jenkinson MD, Lekka E, Abel P, Dawson T, Lea B, Davis C, Lim CSK, Grundy PL, Pendleton M, Lord H, Mackinnon M, Williamson A, James A, Stewart W, Clark B, Chalmers A, Merve A, Zhang X, Marino S, Miller S, Rogers HA, Lyon P, Rand V, Adamowicz-Brice M, Clifford SC, Hayden JT, Dyer S, Pfister S, Korshunov A, Brundler MA, Lowe J, Coyle B, Grundy RG, Nankivell M, Mulvenna P, Barton R, Wilson P, Faivre-Finn C, Pugh C, Langley R, Ngoga D, Tennant D, Williams A, Moss P, Cruickshank G, Owusu-Agyemang K, Bell S, Stewart W, St.George J, Piccirillo SG, Watts C, Qadri S, Pirola E, Jenkinson M, Brodbelt A, Rahman R, Rahman C, Smith S, MacArthur D, Rose F, Shakesheff K, Grundy R, Carroll C, Watson P, Hawkins M, Spoudeas H, Walker D, Holland T, Ring H, Rooney A, McNamara S, Mackinnon M, Fraser M, Rampling R, Carson A, Grant R, Royds J, Al Nadaf S, Ahn A, Chen YJ, Wiles A, Jellinek D, Braithwaite A, Baguley B, MacFarlane M, Hung N, Slatter T, Rusbridge S, Walmsley N, Griffiths S, Wilford P, Rees J, Ryan D, Watts C, Liu P, Galavotti S, Shaked-Rabi M, Tulchinsky E, Brandner S, Jones C, Salomoni P, Schulte A, Gunther HS, Zapf S, Riethdorf S, Westphal M, Lamszus K, Selvanathan SK, Hammouche S, Salminen HJ, Jenkinson MD, Setua S, Watts C, Welland ME, Shevtsov M, Khachatryan W, Kim A, Samochernych K, Pozdnyakov A, Guzhova IV, Romanova IV, Margulis B, Smith S, Rahman R, Rahman C, Barrow J, Macarthur D, Rose F, Grundy R, Smith S, Long A, Barrow J, Macarthur D, Coyle B, Grundy R, Maherally Z, Smith JR, Dickson L, Pilkington GJ, Prabhu S, Harris F, Lea R, Snape TJ, Sussman M, Wilne S, Whitehouse W, Chow G, Liu JF, Walker D, Snape T, Karakoula A, Rowther F, Warr T, Williamson A, Mackinnon M, Zisakis A, Varsos V, Panteli A, Karypidou O, Zampethanis A, Fotovati A, Abu-Ali S, Wang PS, Deleyrolle L, Lee C, Triscott J, Chen JY, Franciosi S, Nakamura Y, Sugita Y, Uchiumi T, Kuwano M, Leavitt BR, Singh SK, Jury A, Jones C, Wakimoto H, Reynolds BA, Pallen CJ, Dunn SE, Shepherd S, Scott S, Bowyer D, Wallace L, Hacking B, Mohsen L, Jena R, Gillard J, Price S, Lee C, Fotovati A, Verraeult M, Wakimoto H, Reynolds B, Dunham C, Bally M, Hukin J, Singhal S, Singh S, Dunn S. Abstracts from the 2011 BNOS Conference, June 29 - July 1, 2011, Homerton College, Cambridge. Neuro Oncol 2011. [DOI: 10.1093/neuonc/nor144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Eustace AJ, Kennedy S, Larkin A, Mahgoub T, Tryfonopoulos D, O'Driscoll L, Clynes M, Crown J, O'Donovan N. Identification of predictive biomarkers for dasatinib treatment of metastatic melanoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, O'Donovan N. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol 2010; 22:68-73. [PMID: 20647220 DOI: 10.1093/annonc/mdq349] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND although trastuzumab has improved the prognosis for HER-2-positive breast cancer patients, not all HER-2-positive breast tumours respond to trastuzumab treatment and those that initially respond frequently develop resistance. Insulin-like growth factor-1 receptor (IGF1R) signalling has been previously implicated in trastuzumab resistance. We tested IGF1R inhibition to determine if dual targeting of HER-2 and IGF1R improves response in cell line models of acquired trastuzumab resistance. MATERIALS AND METHODS HER-2, IGF1R, phospho-HER-2, and phospho-IGF1R levels were measured by enzyme-linked immunosorbent assays in parental and trastuzumab-resistant SKBR3 and BT474 cells. IGF1R signalling was targeted in these cells using both small interfering RNA (siRNA) and the tyrosine kinase inhibitor, NVP-AEW541. RESULTS IGF1R levels were significantly increased in the trastuzumab-resistant model, SKBR3/Tr, compared with the parental SKBR3 cell line. In both the SKBR3/Tr and BT474/Tr cell lines, inhibition of IGF1R expression with siRNA or inhibition of tyrosine kinase activity by NVP-AEW541 significantly increased response to trastuzumab. The dual targeting approach also improved response in the parental SKBR3 cells but not in the BT474 parental cells. CONCLUSIONS our results confirm that IGF1R inhibition improves response to trastuzumab in HER-2-positive breast cancer cells and suggest that dual targeting of IGF1R and HER-2 may improve response in HER-2-positive tumours.
Collapse
Affiliation(s)
- B C Browne
- National Institute for Cellular Biotechnology, Dublin City University, Dublin 9
| | - J Crown
- National Institute for Cellular Biotechnology, Dublin City University, Dublin 9; Department of Medical Oncology, St. Vincent's University Hospital, Dublin 4, Ireland
| | - N Venkatesan
- Division of Hematology and Oncology, University of California, Los Angeles, CA, USA
| | - M J Duffy
- Department of Pathology and Laboratory Medicine, St Vincent's University Hospital, and UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin 4, Ireland
| | - M Clynes
- National Institute for Cellular Biotechnology, Dublin City University, Dublin 9
| | - D Slamon
- Division of Hematology and Oncology, University of California, Los Angeles, CA, USA
| | - N O'Donovan
- National Institute for Cellular Biotechnology, Dublin City University, Dublin 9.
| |
Collapse
|
12
|
Eustace AJ, Mahgoub T, Kennedy S, Crown J, Larkin A, Tryfonopoulos D, O'Driscoll L, Clynes M, O'Donovan N. Targeting SRC kinase (SRC) in melanoma cells. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8584] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Germano S, Rani S, Kennedy S, Crown J, Clynes M, O'Driscoll L. Melanoma-associated antigen family protein-D4: clinical significance and functional relevance in breast cancer. Breast Cancer Res 2010. [PMCID: PMC2875594 DOI: 10.1186/bcr2529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Jampílek J, Dolezal M, Kunes J, Víchová P, Jun D, Hanika J, O'Connor R, Clynes M. Synthesis of (2E)-2-methyl-3-(4-{[4-(quinolin-2-ylmethoxy)phenyl]sulfanyl}phenyl)prop-2-enoic acid (VUFB 20609) and 2-methyl-3-(4-{[4-(quinolin-2-ylmethoxy)phenyl]sulfanyl}phenyl)propanoic acid (VUFB 20584) as potential antileukotrienic agents. J Pharm Pharmacol 2010; 56:783-94. [PMID: 15231044 DOI: 10.1211/0022357023484] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Abstract
The Synthesis of (2E)-2-methyl-3-(4-{[4-(quinolin-2-ylmethoxy)phenyl]sulfanyl}phenyl) prop-2-enoic acid (VUFB 20609) and racemic 2-methyl-3-(4-{[4-(quinolin-2-ylmethoxy) phenyl]sulfanyl}phenyl)propanoic acid (VUFB 20584) as new potential antileukotrienic drugs are described. Due to a low reactivity of the 4-substituted aryl bromides (coupling of the 4-substituted aryl bromides do not provide an activating functional group with 4-methoxybenzene-1-thiol), special conditions, in particular specific heterogeneous copper catalysts, were used. Catalytic hydrogenation of the conjugated double bond on Pd/C in the presence of the sulfanyl group is discussed. In-vitro cytotoxicity testing was performed using a microplate colorimetric acid phosphatase assay. Antiplatelet activity was evaluated using an in-vitro test in human platelet-rich plasma. Some substances inhibited arachidonic acid-induced platelet aggregation.
Collapse
Affiliation(s)
- J Jampílek
- Research Centre LN00B125, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Qadir Z, Qadir Z, Crown J, Crown J, Jensen M, Clynes M, Slamon D, O'Donovan N. Combining HSP90 Inhibition with Standard Therapies for HER2 Positive Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-5055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HSP90 is required for the stability and activity of HER2 and downstream proteins, such as Akt, which play a key role in cell survival. We aimed to assess the anti-tumor effects of the HSP90 inhibitor NVP-AUY922 in HER-2 positive breast cancer cell lines.Methods: HER2 positive breast cancer cell lines with varied sensitivity to trastuzumab (Sensitive: BT474, SKBR3, MDA-MB-361; acquired resistance: BT474Res, SKBR3Res; innate resistance: HCC1419, HCC1954, MDA-MB-453) were treated with the HSP90 inhibitor NVP-AUY922 (Novartis) and trastuzumab. IC50s were determined using the acid phosphatase assay. HER2, Akt and HSP90 levels were determined by immunoblotting after treatment with NVP-AUY922. Combinations of NVP-AUY922 with trastuzumab were tested in BT474, BT474Res, SKBR3, SKBR3Res, HCC1954, and MDA-MB-361 cells. Combinations with docetaxel, cisplatin and 5'-deoxy-5-fluorouridine (5-DFUR) were tested in BT474, SKBR3, HCC1954, MDA-MB-453 and MDA-MB-361 cells.Results: All of the HER2 positive cells were sensitive to NVP-AUY922, with IC50s ranging from 5.5 to 16.4 nM and NVP-AUY922 treatment reduced HER2 and Akt levels in a dose dependent manner. Combined treatment with NVP-AUY922 (10 nM) and trastuzumab (10 nM) showed significantly greater inhibition of growth than either trastuzumab or NVP-AUY922 alone in BT474 and BT474Res cell lines (p<0.005). In SKBR3, SKBR3Res, HCC1954, MDA-MB-453 and MDA-MB-361 cells, dual treatment with NVP-AUY922 and trastuzumab did not significantly increase response compared to NVP-AUY922 alone (Table 1). Combinations of docetaxel, cisplatin or 5-DFUR with NVP-AUY922 were antagonistic in all cell lines tested (CI values >1).Conclusions: This study demonstrates that NVP-AUY922 has anti-tumour activity in HER2 positive breast cancers regardless of sensitivity to trastuzumab. The antagonistic interactions observed for combinations of NVP-AUY922 with chemotherapy do not favour clinical evaluation of concurrent administration of NVP-AUY922 with chemotherapy. However, alternative scheduling or combinations with other targeted therapies warrants further investigation.Table 1: Percentage growth in response to NVP-AUY922 and trastuzumab. BT474BT474ResSKBR3SKBR3ResHCC1954MDA-MB-361Trastuzumab53.3 +/- 4.990.4 +/- 7.669.5 +/- 16.179.5 +/- 8.2102.9 +/- 15.558.4 +/- 3.3AUY92255.0 +/- 1.192.6 +/- 11.933.3 +/- 9.719.1 +/- 6.152.2 +/- 13.88.2 +/- 6.2Tras+AUY92222.0 +/- 2.3*59.7 +/- 17.5*30.6 +/- 7.518.3 +/- 4.347.2 +/- 3.42.5 +/- 2.2
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5055.
Collapse
Affiliation(s)
- Z. Qadir
- 1Dublin City University, Ireland
| | - Z. Qadir
- 2St Vincent's University Hospital, Ireland
| | - J. Crown
- 1Dublin City University, Ireland
| | - J. Crown
- 2St Vincent's University Hospital, Ireland
| | - M. Jensen
- 3Novartis Institutes for Biomedical Research, Switzerland
| | | | - D. Slamon
- 4University of California, Los Angeles, CA,
| | | |
Collapse
|
16
|
Muniyappa MK, Dowling P, Henry M, Meleady P, Doolan P, Gammell P, Clynes M, Barron N. MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. Eur J Cancer 2009; 45:3104-18. [PMID: 19818597 DOI: 10.1016/j.ejca.2009.09.014] [Citation(s) in RCA: 101] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2009] [Revised: 08/31/2009] [Accepted: 09/11/2009] [Indexed: 12/13/2022]
Abstract
In this study we have identified a functional role for miR-29a in cancer cell invasion and proliferation. MiRNA expression profiling of human NSCLC cell lines indicated that miR-29a levels were reduced in more invasive cell lines. Exogenous overexpression of miR-29a in both lung and pancreatic cancer cell lines resulted in a significant reduction in the invasion phenotype, as well as in proliferation. 2D DIGE proteomic profiling of cells transfected with pre-miR-29a or anti-miR-29a resulted in the identification of over 100 differentially regulated proteins. The fold change of protein expression was generally modest--in the range 1.2-1.7-fold. Only 14 were predicted computationally to have miR-29a seed sequences in their 3' UTR region. Subsequent studies using siRNA to knock down several candidate proteins from the 2D DIGE experiment identified RAN (a member of the RAS oncogene family) which significantly reduced the invasive capability of a model lung cancer cell line. We conclude that miR-29a has a significant anti-invasive and anti-proliferative effect on lung cancer cells in vitro and functions as an anti-oncomir. This function is likely mediated through the post-transcriptional fine tuning of the cellular levels of several proteins, both directly and indirectly, and in particular we provide some evidence that RAN represents one of these.
Collapse
Affiliation(s)
- M K Muniyappa
- National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Doolan P, Clynes M, Kennedy S, Mehta JP, Germano S, Ehrhardt C, Crown J, O'Driscoll L. TMEM25, REPS2 and Meis 1: favourable prognostic and predictive biomarkers for breast cancer. Tumour Biol 2009; 30:200-9. [PMID: 19776672 DOI: 10.1159/000239795] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2009] [Accepted: 07/02/2009] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND/AIMS A panel of prognostic and predictive biomarkers would contribute to personalized treatment of breast cancer patients. However, many such biomarkers have yet to be identified and evaluated. The aim of this study was to investigate the relevance of 3 such putative biomarkers. METHODS TMEM25, REPS2 and Meis 1 expression was investigated by qRT-PCR, in triplicate, in 103 breast tumour biopsies procured in 1993-1994. Normal breast tissue specimens were also analysed for comparative purposes. Univariate and multivariate analyses were used to identify associations between expression of these transcripts as well as patients' clinicopathological and survival data. RESULTS TMEM25, REPS2 and Meis 1 transcripts were detected in approximately 52, 78 and 40% of tumour specimens, respectively. Expression of each of the 3 genes was indicative of extended survival times from diagnosis [association between relapse-free survival (RFS) and TMEM25, p = 0.0002; REPS2, p = 0.0287; association between overall survival (OS) and TMEM25, p = 0.001; REPS2, p = 0.0131; Meis 1, p = 0.0255]. Presence of TMEM25 and Meis 1 was associated with oestrogen receptor-positive (TMEM25, p < 0.0005; Meis 1, p = 0.011), lower-grade (TMEM25, p = 0.002; Meis 1, p = 0.001) tumours. Multivariate analysis indicated TMEM25 expression to be an independent prognostic factor for extended RFS (p = 0.011) and OS (p = 0.001). Furthermore, for patients who received adjuvant chemotherapy, significantly longer survival times were achieved if their tumours expressed TMEM25 (OS, p = 0.031; RFS, p = 0.0181) and REPS2 (OS, p = 0.011). While expression of these mRNAs was generally absent from triple-negative breast tumours, statistical significance was not achieved. CONCLUSION Our results suggest that TMEM25, REPS2 and Meis 1 mRNAs may be useful members of a panel of favourable prognostic and predictive markers for breast cancer and an understanding of their function may provide useful information about this disease.
Collapse
Affiliation(s)
- P Doolan
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Mahgoub T, Clynes M, Crown J, O'Donovan N. 9322 Novel protein kinase inhibitors in melanoma. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71966-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
19
|
Sheikh R, O'connor R, Walsh N, Clynes M, Mcdermott R. 6632 Characterisation of the response of pancreatic cancer cells to treatment with chemotherapeutic agents alone and in combination with tyrosine kinase inhibitors. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71353-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
20
|
Abstract
e14605 Background: Triple-negative breast cancers (TNBC) lack expression of oestrogen, progesterone, and are HER-2 normal. TNBC cell lines have displayed greater sensitivity to growth inhibition by the multi-target kinase inhibitor, dasatinib, than luminal or HER- 2 positive breast cancer cell lines. The aim of this study was to assess the direct anti-tumor effects of dasatinib in combination with chemotherapy in TNBC. Methods: Four TNBC cell lines (MDA-MB-231, HCC-1143, HCC-1937, MDA-MB-468) were treated with dasatinib in combination with docetaxel, cisplatin or 5'-5' DFUR. IC50 values were calculated for each drug alone by determining response in a 5-day proliferation (acid phosphatase) assay. Combination index (CI) values were determined, using CalcuSyn, to assess the interaction between drugs. Results: Three of the cell lines (MDA-MB-231, HCC- 1143, HCC-1937) were sensitive to dasatinib (IC50 < 1 μM) whereas MDA-MB-468 was resistant (IC50 > 1 μM) (Table). In MDA-MB-231 and HCC-1143 cells, combined treatment with dasatinib and 5'-5'-DFUR displayed synergy (CI<1.0), whereas the combination was additive in HCC-1937 cells (CI=0.98). Combined treatment with dasatinib and cisplatin was synergistic in the three dasatinib sensitive cell lines (CI<1.0). Dasatinib in combination with docetaxel displayed moderate synergy in MDA-MB-231 and HCC-1937 cells (CI<1.0), but was antagonistic in HCC-1143 cells (CI>1.0). Conclusions: Our findings show that the combination of dasatinib with either 5'-5'-DFUR or cisplatin is synergistic in TNBC cell lines, and suggest that combinations of dasatinib with chemotherapy may improve response in triple negative breast cancer patients. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Tryfonopoulos
- St Vincent's University Hospital and NICB, Dublin, Ireland; National Institute for Cellular Biotechnology, DCU, Dublin, Ireland
| | - N. O'Donovan
- St Vincent's University Hospital and NICB, Dublin, Ireland; National Institute for Cellular Biotechnology, DCU, Dublin, Ireland
| | - B. Corkery
- St Vincent's University Hospital and NICB, Dublin, Ireland; National Institute for Cellular Biotechnology, DCU, Dublin, Ireland
| | - M. Clynes
- St Vincent's University Hospital and NICB, Dublin, Ireland; National Institute for Cellular Biotechnology, DCU, Dublin, Ireland
| | - J. Crown
- St Vincent's University Hospital and NICB, Dublin, Ireland; National Institute for Cellular Biotechnology, DCU, Dublin, Ireland
| |
Collapse
|
21
|
Abstract
e14573 Background: HSP90 is required for the stability and activity of HER2 and downstream proteins, such as Akt, which play a key role in survival. We aimed to assess the anti-tumor effect of the HSP90 inhibitor NVP-AUY922 in HER-2 positive breast cancer cell lines. Methods: HER2 positive breast cancer cell lines with varied sensitivity to trastuzumab (Sensitive: BT474, SKBR3; acquired resistance: BT474Res, SKBR3Res; innate resistance: HCC1419, HCC1954, MDA-MB-453) were treated with the HSP90 inhibitor NVP-AUY922 (Novartis) and trastuzumab. IC50s were determined using the acid phosphatase assay. HER2, Akt and HSP90 levels were determined by immunoblotting after treatment with NVP-AUY922. Combinations of NVP-AUY922 with docetaxel, cisplatin and 5'-deoxy-5-fluorouridine (5-DFUR) were tested in BT474 and SKBR3 cells. Results: All of the HER2 positive cells were sensitive to NVP-AUY922, with IC50s ranging from 5.5 to 16.4 nM. Combined treatment with NVP-AUY922 (10 nM) and trastuzumab (10 nM) showed significantly greater inhibition of growth than either trastuzumab or NVP-AUY922 alone in BT474 and BT474Res cell lines (p<0.005). In SKBR3 and SKBR3Res cells, dual treatment with NVP-AUY922 and trastuzumab did not significantly increase response compared to NVP-AUY922 alone ( Table 1 ). Treatment with NVP-AUY922 resulted in a dose-dependent decrease in HER2 and Akt levels in trastuzumab-sensitive and -resistant cells. Combinations of docetaxel, cisplatin or 5-DFUR with NVP- AUY922 were antagonistic in both BT474 and SKBR3 cells (CI values >1). Conclusions: This study demonstrates that NVP-AUY922 has anti-tumor activity in trastuzumab-sensitive, and in both innate and acquired trastuzumab-resistant HER2 positive breast cancer cells. The antagonistic interactions observed for combinations of NVP-AUY922 with chemotherapy do not favour clinical evaluation of such combinations. However, combinations with other targeted therapies, such as trastuzumab, warrant further investigation. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- Z. Qadir
- National Institute of Cellular Biotechnology, Dublin, Ireland; St. Vincent's University Hospital, Dublin, Ireland; Novartis Institute of Biomedical Research, Basel, Switzerland; University of California, Los Angeles, CA
| | - J. Crown
- National Institute of Cellular Biotechnology, Dublin, Ireland; St. Vincent's University Hospital, Dublin, Ireland; Novartis Institute of Biomedical Research, Basel, Switzerland; University of California, Los Angeles, CA
| | - M. R. Jensen
- National Institute of Cellular Biotechnology, Dublin, Ireland; St. Vincent's University Hospital, Dublin, Ireland; Novartis Institute of Biomedical Research, Basel, Switzerland; University of California, Los Angeles, CA
| | - M. Clynes
- National Institute of Cellular Biotechnology, Dublin, Ireland; St. Vincent's University Hospital, Dublin, Ireland; Novartis Institute of Biomedical Research, Basel, Switzerland; University of California, Los Angeles, CA
| | - D. Slamon
- National Institute of Cellular Biotechnology, Dublin, Ireland; St. Vincent's University Hospital, Dublin, Ireland; Novartis Institute of Biomedical Research, Basel, Switzerland; University of California, Los Angeles, CA
| | - N. O'Donovan
- National Institute of Cellular Biotechnology, Dublin, Ireland; St. Vincent's University Hospital, Dublin, Ireland; Novartis Institute of Biomedical Research, Basel, Switzerland; University of California, Los Angeles, CA
| |
Collapse
|
22
|
Corkery B, Crown J, Clynes M, O'Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009; 20:862-7. [PMID: 19150933 DOI: 10.1093/annonc/mdn710] [Citation(s) in RCA: 248] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND No proven targeted therapy is currently available for the treatment of triple-negative breast cancer (TNBC). Epidermal growth factor receptor (EGFR) is frequently overexpressed in TNBC. We studied the activity of EGFR antagonists alone, and in combination with chemotherapy, in TNBC cell lines. MATERIALS AND METHODS EGFR and phosphorylated EGFR were measured by enzyme-linked immunosorbent assay. Sensitivity to EGFR inhibitors alone and in combination with chemotherapy was assessed. Effects of gefitinib on EGFR signalling and cell cycle were also examined. RESULTS EGFR was overexpressed in the TNBC compared with the human epidermal growth factor receptor 2 (HER-2)-positive cell lines. Phosphorylation of EGFR was detected in the TNBC cells in response to epidermal growth factor stimulation and was blocked by gefitinib treatment. However, the TNBC cell lines were less sensitive to EGFR inhibition than the HER-2-positive cell lines. Response to gefitinib was associated with reduced phosphorylation of both mitogen activated protein kinase (MAPK) and Akt and induction of G(1) arrest. Gefitinib enhanced response to both carboplatin and docetaxel in the TNBC cells, and the triple combination of gefitinib, carboplatin and docetaxel was synergistic. CONCLUSIONS Although the TNBC cells are less sensitive to EGFR inhibition than the HER-2-positive cell lines, gefitinib enhanced response to chemotherapy. Gefitinib combined with carboplatin and docetaxel warrants further investigation in TNBC.
Collapse
Affiliation(s)
- B Corkery
- National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin
| | | | | | | |
Collapse
|
23
|
Abstract
Intrinsic and acquired resistance to chemotherapy is a serious problem for many cancer patients. Cancer cells appear to have the capacity to generate variants resistant to any anticancer drug. Tumours, and even individual cancer cells, can exhibit multiple mechanisms of resistance simultaneously. In order to overcome resistance it may be necessary to achieve a high rate of tumour cell kill before multiple resistance mechanisms can develop, and/or to develop therapies which simultaneously target several resistance mechanisms. Mechanisms of resistance described so far include 'bulk' mechanisms (e.g. related to blood and drug supply, and to oxygenation), mechanisms relating to population cell kinetics, and mechanisms at the cellular level including altered expression of drug target proteins, drug transporter proteins, drug metabolising enzymes, and proteins which regulate cell death pathways. This volume brings together up-to-date reviews on all of these aspects written by researchers actively involved in their topic. It is a completely new book, different from its predecessor Multiple Drug Resistance in Cancer - Cellular, Molecular and Clinical Approaches (Kluwer, 1994). Most of the topics and contributors are new, and chapters on the same topics are included only in cases where there have been significant research developments in the interim period. I hope that this volume will bring together different ideas and approaches, and help to encourage their integration to generate new treatments which will cure more cancer patients.
Collapse
|
24
|
Murphy L, Henry M, Meleady P, Clynes M, Keenan J. Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2008; 1784:1184-91. [DOI: 10.1016/j.bbapap.2008.04.014] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/04/2007] [Revised: 04/17/2008] [Accepted: 04/23/2008] [Indexed: 12/17/2022]
|
25
|
Eustace A, Crown J, Clynes M, O'Donovan N. Preclinical evaluation of dasatinib in melanoma cell lines. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)71602-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
26
|
Tryfonopoulos D, O’Donovan N, Clynes M, Crown JP. Preclinical evaluation of sunitinib, alone and in combination with trastuzumab, in HER2 positive breast cancer (BC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.14689] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Kumar N, Maurya P, Gammell P, Dowling P, Clynes M, Meleady P. Proteomic Profiling of Secreted Proteins from CHO Cells Using Surface-Enhanced Laser Desorption Ionization Time-of-Flight Mass Spectrometry. Biotechnol Prog 2008; 24:273-8. [DOI: 10.1021/bp070244o] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
28
|
Abstract
The cytochrome P450 CYP1B1 is consistently overexpressed in tumour cells as compared to their normal counterparts, but its precise role in drug resistance is yet to be defined. It has been reported that transfection of CYP1B1 results in increased resistance to docetaxel in V79 cells (McFadyen et al, 2001). In this study, we analysed changes in expression of CYP1B1 mRNA associated with pulse selection of MCF-7 cells with docetaxel. Docetaxel-selected MCF-7 cells (MCF-7 Txt), which showed increased resistance to this drug as compared to parental MCF-7 cells, showed a noteworthy increase in CYP1B1 mRNA expression, paralleled by increased ethoxyresorufin-O-deethylase (EROD) activity levels. This effect was not observed in cisplatin- or adriamycin-selected MCF-7 cells, or in docetaxel-selected colon, lung or pancreatic carcinoma cells. Short-term treatment with docetaxel induced CYP1B1 mRNA expression in MDA 453 and BT-20 breast carcinoma cells, but not in MCF-7 cells. Transfection of MCF-7 Txt cells with CYP1B1 siRNA did not significantly affect docetaxel-induced toxicity, but it decreased cell survival in the absence of drug. Preincubation of docetaxel with recombinant CYP1B1 did not affect drug toxicity in A549 cells. These results suggest that CYP1B1 does not directly inactivate docetaxel, but rather might promote cell survival in MCF-7 Txt cells, providing an explanation for its association with drug resistance.
Collapse
Affiliation(s)
- V G Martinez
- National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
| | | | | | | |
Collapse
|
29
|
Corkery B, O' Donovan N, Clynes M, Crown J. 2003 ORAL Gefitinib enhances response to chemotherapy in triple-negative Breast Cancer (BrCa). EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70765-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
30
|
O'Driscoll L, Walsh N, Larkin A, Ballot J, Ooi WS, Gullo G, O'Connor R, Clynes M, Crown J, Kennedy S. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma. Anticancer Res 2007; 27:2115-20. [PMID: 17695494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
BACKGROUND Pancreatic cancer is one of the most challenging solid organ malignancies. This is due to its aggressiveness, frequent late presentation as advanced disease and chemoresistance. A better understanding of the molecular basis of its drug resistance is needed. MATERIALS AND METHODS In this study, the first of its kind, the expression of both MDR1 P-gp and MRP-1 protein in pancreatic tumour specimens was examined by immunohistochemistry. Expression of these drug efflux pumps was examined using semi-quantitative immunohistochemistry according to the percentage of cells within the tumour, demonstrating another staining intencity. RESULTS Overall, 93.3% of pancreatic carcinomas expressed MDR1 P-gp, approximately 31% co-expressed MRP-1 with MDR1 P-gp, while 6.7% expressed neither of these proteins. CONCLUSION Our results show that drug efflux pumps, in particular that of MDR1 P-gp, are frequently expressed in pancreatic cancer. While a causative role for these efflux pumps in pancreatic cancer chemoresistance cannot necessarily be concluded, the information presented here should be considered when selecting chemotherapy/drug efflux pump inhibitors for future therapies.
Collapse
Affiliation(s)
- L O'Driscoll
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
14071 Background: Triple-negative BrCa lacks expression of hormone receptors and HER-2 but does express EGFR. It is associated with early relapse and poor survival. There is no targeted therapy for triple-negative BrCa. We are studying the potential role of EGFR inhibition. Methods: EGFR expression was examined in triple-negative BrCa cell lines, (BT20, HCC1937, and MDA-MB-231) by western blot. IC50 assays were determined for three EGFR inhibitors, gefitinib (G) and erlotinib (T), which are small-molecule tyrosine kinase inhibitors, and cetuximab (E) which is a monoclonal antibody against EGFR, and chemotherapy (CRx) drugs docetaxel (D) and carboplatin (P)), using the acid phosphatase assay. The controls were HER2+ BrCa cell lines, BT474 and SKBR3 which express low levels of EGFR. Results: The three triple-negative cell lines over-express EGFR. IC50 values for G and T were significantly higher in the triple-negative than in the HER2+ cell lines. E did not cause significant inhibition in any cell line (max inhibition 20% at 100 μg/ml E). IC50 values for G were lower than for T in the triple-negative cell lines (IC50s for HCC1937: G - 8.4 ± 1.5 μM; T - 26.2 ± 9.3 μM). Combined EGFR inhibition with CRx was tested in HCC1937 cells. G combined with P or with D for 5 days showed an additive effect on inhibition of proliferation ( Table 1 ). Alternate scheduling of the drugs did not significantly influence response. Conclusions: Our results suggest that triple-negative BrCa cells over-express EGFR but are not as sensitive to EGFR inhibition as HER2+ BrCa cells. However, EGFR inhibition may enhance response to CRx in triple-negative BrCa. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. Corkery
- Dublin City University, Dublin, Ireland; St. Vincent’s University Hospital, Elm Park, Dublin, Ireland
| | - N. O’Donovan
- Dublin City University, Dublin, Ireland; St. Vincent’s University Hospital, Elm Park, Dublin, Ireland
| | - M. Clynes
- Dublin City University, Dublin, Ireland; St. Vincent’s University Hospital, Elm Park, Dublin, Ireland
| | - J. Crown
- Dublin City University, Dublin, Ireland; St. Vincent’s University Hospital, Elm Park, Dublin, Ireland
| |
Collapse
|
32
|
Browne BC, Crown J, Venkatesan N, Pegram M, Clynes M, Duffy MJ, Slamon DJ, O’Donovan N. Insulin-like growth factor I receptor (IGF-IR) inhibition in trastuzumab (T) resistant HER2+ breast cancer (BrCa) cells. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14049 Background: IGF-IR signaling interferes with the growth inhibitory action of T in BrCa cell lines and may play a role in clinical resistance to T. We studied the effect of IGF-IR inhibition on T resistance. Methods: HER2 and IGF-IR protein levels were determined by ELISA. T growth inhibition of HER2+ BrCa cell lines was measured by cell counting. HER2 and IGF-IR activity were determined by immunoprecipitation with HER2 and IGF-IR antibodies, followed by western blotting with phospho-tyrosine antibody. The effects of IGF- I/IGF-IR inhibition on proliferation and response to T were investigated. Results: No significant correlation was found between HER2, phospho-HER2 or IGF-IR levels and response to T in 12 HER+ BrCa lines. However, two T-conditioned cell lines show resistance to T (BT474 - 2.6 fold; SKBR3 - 1.8 fold) and have higher levels of phospho-IGF-IR compared to parental cell lines. Neither IGFBP3 nor IGF-IR antibody aIR3 significantly inhibited the growth of T-conditioned cell lines or enhanced the anti-proliferative effects of T. IGF-IR siRNA decreased IGF-IR protein levels and inhibited proliferation (29.8 ± 9.3 %) of T-conditioned SKBR3 cells. IGF-IR siRNA also enhanced T growth inhibition of T-conditioned SKBR3 cells (47.7 ± 13.7 % compared to 17.7 ± 14.8 % for T alone). The small molecule IGF-IR tyrosine kinase inhibitor (TKI), NVP-AEW541, inhibited growth of parental and T-conditioned SKBR3 cells and enhanced response to T (Table). Conclusions: Increased activation of IGF-IR may play a role in resistance to T. Inhibition of IGF-I ligand binding does not appear to alter IGF-IR mediated T-resistance. However, reducing IGF-IR protein levels or blocking IGF-IR TK activity improves response to T in resistant cells. Thus, the combination of IGF-IR TKIs, such as NVP-AEW541, with T may be beneficial for T-resistant HER2+ BrCa. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- B. C. Browne
- National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent’s University Hospital, Dublin, Ireland; University of California at Los Angeles, Los Angeles, CA
| | - J. Crown
- National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent’s University Hospital, Dublin, Ireland; University of California at Los Angeles, Los Angeles, CA
| | - N. Venkatesan
- National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent’s University Hospital, Dublin, Ireland; University of California at Los Angeles, Los Angeles, CA
| | - M. Pegram
- National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent’s University Hospital, Dublin, Ireland; University of California at Los Angeles, Los Angeles, CA
| | - M. Clynes
- National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent’s University Hospital, Dublin, Ireland; University of California at Los Angeles, Los Angeles, CA
| | - M. J. Duffy
- National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent’s University Hospital, Dublin, Ireland; University of California at Los Angeles, Los Angeles, CA
| | - D. J. Slamon
- National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent’s University Hospital, Dublin, Ireland; University of California at Los Angeles, Los Angeles, CA
| | - N. O’Donovan
- National Institute for Cellular Biotechnology, Dublin, Ireland; St Vincent’s University Hospital, Dublin, Ireland; University of California at Los Angeles, Los Angeles, CA
| |
Collapse
|
33
|
Murphy L, Clynes M, Keenan J. Proteomic analysis to dissect mitoxantrone resistance-associated proteins in a squamous lung carcinoma. Anticancer Res 2007; 27:1277-84. [PMID: 17593620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
BACKGROUND Mitoxantrone resistance has been related to the expression of a drug efflux pump breast cancer resistance pump (BCRP) but little is known of the intracellular protein changes. In this work, differential protein expression in a squamous lung carcinoma cell line, DLKP, and its mitoxantrone-resistant variant (DLKP-Mitox) was investigated to elucidate other changes associated with mitoxantrone resistance. MATERIALS AND METHODS Differential protein expression between DLKP and DLKP-Mitox was investigated using 2D-DIGE technology. Proteins of interest were identified by MALDI-ToF mass spectrometry. Western blotting was used to confirm and validate some of these changes. RESULTS Biological variation analysis in Decyder software revealed a total of 343 proteins to be differentially regulated with p < 0.05. Identification of 61 proteins of interest by mass spectrometry revealed changes in proteins involved in many cellular processes including apoptosis and differentiation. CONCLUSION Alterations in these cellular processes and proteins present alternative sites to circumvent resistance to mitoxantrone.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors
- ATP Binding Cassette Transporter, Subfamily B, Member 1/biosynthesis
- ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics
- ATP Binding Cassette Transporter, Subfamily G, Member 2
- ATP-Binding Cassette Transporters/antagonists & inhibitors
- ATP-Binding Cassette Transporters/biosynthesis
- ATP-Binding Cassette Transporters/genetics
- Acridines/pharmacology
- Antineoplastic Agents/pharmacology
- Carcinoma, Squamous Cell/drug therapy
- Carcinoma, Squamous Cell/genetics
- Carcinoma, Squamous Cell/metabolism
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Electrophoresis, Gel, Two-Dimensional/methods
- Gene Expression Regulation, Neoplastic
- Humans
- Lung Neoplasms/drug therapy
- Lung Neoplasms/genetics
- Lung Neoplasms/metabolism
- Mitoxantrone/pharmacology
- Neoplasm Proteins/antagonists & inhibitors
- Neoplasm Proteins/biosynthesis
- Neoplasm Proteins/genetics
- Proteomics/methods
- Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
- Tetrahydroisoquinolines/pharmacology
Collapse
Affiliation(s)
- L Murphy
- National Institute of Cellular Biology, Dublin City University, Ireland
| | | | | |
Collapse
|
34
|
Dowling P, Maurya P, Meleady P, Glynn SA, Dowd AJ, Henry M, Clynes M. Purification and identification of a 7.6-kDa protein in media conditioned by superinvasive cancer cells. Anticancer Res 2007; 27:1309-17. [PMID: 17593624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
BACKGROUND Selection of the human drug sensitive and invasive cell line (MDA-MB-435S-F) with the chemotherapeutic agent paclitaxel, resulted in the development of drug resistant cell lines displaying enhanced invasion-related characteristics. MATERIALS AND METHODS Serum-free conditioned media from the human cancer drug-sensitive and invasive cell line (MDA-MB-435S-F) and its paclitaxel-resistant superinvasive variant (MDA-MB-435S-F/Taxol10p4pSI) were analyzed using Surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). RESULTS A differentially expressed protein was observed at 7.6 kDa, which was 4-fold up-regulated in MDA-MB-435S-F/Taxol10p4pSI. The differentially expressed protein was identified using matrix-assisted laser desorption ionization tandem time-of-flight mass spectrometry (MALDI-TOF/TOF MS), as a fragment of bovine transferrin. The transferrin receptor was also found to be overexpressed in the superinvasive cell line. CONCLUSION Cleavage of serum proteins such as transferrin could provide a valuable source of markers for malignant tumours and could also play a role in aspects of cancer pathogenesis, such as tumour cachexia.
Collapse
MESH Headings
- Adult
- Biomarkers, Tumor/chemistry
- Biomarkers, Tumor/isolation & purification
- Breast Neoplasms/chemistry
- Breast Neoplasms/drug therapy
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Cell Line, Tumor
- Culture Media, Conditioned
- Drug Resistance, Neoplasm
- Female
- Humans
- Neoplasm Invasiveness
- Neoplasm Proteins/chemistry
- Neoplasm Proteins/isolation & purification
- Paclitaxel/pharmacology
- Peptide Fragments/chemistry
- Peptide Fragments/isolation & purification
- Receptors, Transferrin/biosynthesis
- Receptors, Transferrin/chemistry
- Receptors, Transferrin/isolation & purification
- Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods
- Transferrin/chemistry
- Transferrin/isolation & purification
Collapse
Affiliation(s)
- P Dowling
- National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
| | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
Breast cancer, the most common form of cancer among women in North America and almost all of Europe, is a significant health problem in terms of both morbidity and mortality. It is estimated that each year this disease is diagnosed in over one million people worldwide and is the cause of more than 400,000 deaths. Although chemotherapy forms part of a successful treatment regime in many cases, as few as 50% patients may benefit from this, as a result of intrinsic or acquired multiple drug resistance (MDR). Through the use of in vitro cell culture models, a number of mechanisms of MDR have been identified; many, if not all, of which may contribute to breast cancer resistance in the clinical setting. This phenomenon is complicated by the likely multi-factorial nature of clinical resistance combined with the fact that, although apparently studied extensively in breast cancer, reported analyses have been performed using a range of analytical techniques; many on small sub-groups of patients, with different clinicopathological characteristics and receiving a range of therapeutic approaches. Larger defined studies, using standardised genomic and proteomics profiling approaches followed by functional genomics studies, are necessary in order to definitively establish the degree of complexity contributing to drug resistance and to identify novel therapeutic approaches - possibly involving chemotherapy, drug resistance modulators, and novel targeted therapies - to combat this disease.
Collapse
Affiliation(s)
- L O'Driscoll
- National Institute for Cellular Biotechnology, Dublin City University, Ireland.
| | | |
Collapse
|
36
|
Abstract
13132 Background: ErbB2 is overexpressed in approximately 25–30% of breast cancers. Recent studies have shown that overexpression of ErbB2 is also frequently associated with expression of ErbB1 and that ErbB1 expression influences response to ErbB2 inhibition. The aim of this study was to investigate the effects of dual targeting of ErbB1 and ErbB2 in ErbB2 overexpressing breast cancer cell lines. Methods: Combinations of Trastuzumab (Herceptin), Gefitinib (Iressa) and Lapatinib (GW572016) were tested in two ErbB2 and ErbB1 positive breast cancer cell lines, SKBR3 and BT474. Proliferation assays were performed using the acid phosphatase assay and apoptosis was measured using the Cell Death Detection ELISA (Roche). The average combinations index (CI) values at ED25, ED50 and ED75 were determined using CalcuSyn. Results: With regard to inhibition of proliferation, dual targeting with Trastuzumab and Gefitinib is additive (CI=0.8) in SKBR3 cells and synergistic (CI=0.6) in BT474 cells. Combined treatment with Trastuzumab and Lapatinib is synergistic (CI=0.5) in SKBR3 cells and additive (CI=1.0) in BT474 cells. Dual targeting with Gefinitib and Lapatinib is antagonistic in both cell lines. Trastuzumab (10 nM) alone and Gefitinib (5 μM) alone did not induce significant apoptosis in SKBR3 cells whereas Lapatinib (0.75 μM) alone induced apoptosis and in combination with Trastuzumab enhanced apoptosis induction. Combined treatment with Trastuzumab (10 nM) and Gefitinib (5 μM) induced apoptosis comparable to Lapatinib alone (0.75 μM). Conclusions: Our results suggest that dual targeting of ErbB1 and ErbB2 with combinations of the monoclonal antibody, Trastuzumab and tyrosine kinase inhibitors may improve response to treatment in a sub-group of patients with ErbB2 overexpressing tumours that also express ErbB1. Interestingly, the apoptosis assays suggest that inhibition of both ErbB1 and ErbB2 is required to efficiently induce apoptosis in cells which express both receptors. [Table: see text]
Collapse
Affiliation(s)
- N. O’Donovan
- Dublin City University, Dublin, Ireland; St. Vincent’s University Hospital, Dublin, Ireland
| | - J. P. Crown
- Dublin City University, Dublin, Ireland; St. Vincent’s University Hospital, Dublin, Ireland
| | - M. Clynes
- Dublin City University, Dublin, Ireland; St. Vincent’s University Hospital, Dublin, Ireland
| |
Collapse
|
37
|
O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol 2006; 59:79-87. [PMID: 16642371 DOI: 10.1007/s00280-006-0240-7] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2006] [Accepted: 03/20/2006] [Indexed: 12/16/2022]
Abstract
PURPOSE Multi-drug resistance mediated by ATP-binding cassette trans-membrane protein pumps is an important cause of cancer treatment failure. Sulindac has been shown to be a competitive substrate for the clinically important resistance protein, multi-drug resistance protein-1 (MRP-1), and thus might enhance the anti-cancer activity of substrate chemotherapeutic agents, e.g. anthracyclines. METHODS We conducted a dose-escalating, single arm, prospective, open label, non-randomised phase I trial of epirubicin (75 mg/m(2)) in combination with escalating oral doses of sulindac (0-800 mg) in patients with advanced cancer to identify an appropriate dose of sulindac to use in future resistance studies. Anthracycline and sulindac pharmacokinetics were studied in cycles 1 and 3. RESULTS Seventeen patients (8 breast, 3 lung, 2 bowel, 1 melanoma, 1 renal, 1 ovarian and 1 of unknown primary origin, 16/17 having had prior chemotherapy) were enrolled. Eight patients received a full six cycles of treatment; 14 patients received three or more cycles. Dose-limiting toxicity was observed in two patients at 800 mg sulindac (1 renal impairment, 1 fatal haemoptysis in a patient with advanced lung cancer), and sulindac 600 mg was deemed to be the maximum tolerated dose. Sulindac had no effect on epirubicin pharmacokinetics. Among 15 patients with evaluable tumour, two partial responses were seen (malignant melanoma and breast cancer). Four others had prolonged stable disease. CONCLUSION Epirubicin 75 mg/m(2) and sulindac 600 mg are the recommended doses for phase II studies for these agents in combination.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors
- ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism
- Adult
- Aged
- Anti-Inflammatory Agents, Non-Steroidal/adverse effects
- Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics
- Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
- Antibiotics, Antineoplastic/adverse effects
- Antibiotics, Antineoplastic/therapeutic use
- Chemotherapy, Adjuvant
- Creatinine/blood
- Dose-Response Relationship, Drug
- Drug Resistance, Multiple/drug effects
- Drug Resistance, Neoplasm/drug effects
- Epirubicin/adverse effects
- Epirubicin/therapeutic use
- Female
- Humans
- Immunohistochemistry
- Male
- Middle Aged
- Myocardium/metabolism
- Neoplasms/drug therapy
- Neoplasms/metabolism
- Neoplasms/pathology
- Platelet Count
- Prospective Studies
- Sulindac/adverse effects
- Sulindac/pharmacokinetics
- Sulindac/therapeutic use
- Troponin/metabolism
Collapse
Affiliation(s)
- R O'Connor
- The National Institute for Cellular Biotechnology, Dublin City University, Dublin, 9, Ireland.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Abstract
Breast cancer is a significant health problem in terms of both morbidity and mortality, with approximately 12% of women directly affected by this disease. Chemotherapy, given to patients with earlier stage disease, has a good survival impact and may contribute to cure. The failure of chemotherapeutic drugs to eradicate cancer cells in more advanced disease states may be due to intrinsic or acquired drug resistance, including multiple drug resistance. The drug resistance observed in breast cancer patients is likely to be multifactorial, involving mechanisms such as altered expression and/or activity of drug efflux pumps, nuclear DNA-binding enzymes, metabolizing and conjugating enzymes, and mismatch repair deficiency. More extensive transcriptomic and proteomic analyses of breast tumour and normal biopsies, followed by functional genomic studies in relevant cell line models, should increase our understanding of this phenomenon and lead to therapies being individualized for identifiable subgroups of breast cancer patients.
Collapse
Affiliation(s)
- L O'Driscoll
- National Institute for Cellular Biotechnology, Dublin City University, Ireland.
| | | |
Collapse
|
39
|
Glynn SA, Gammell P, Heenan M, O'Connor R, Liang Y, Keenan J, Clynes M. A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin. Br J Cancer 2004; 91:1800-7. [PMID: 15505620 PMCID: PMC2410060 DOI: 10.1038/sj.bjc.6602221] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Doxorubicin- and paclitaxel-selected variants of an in vitro invasive clonal population of the human breast cancer cell line, MDA-MB-435S, were established by pulse selection, and exhibited a novel ‘superinvasive’ phenotype. This phenotype is characterised by an ability to relocate to another surface following invasion through matrigel and membrane pores, by decreased adhesion to extracellular matrix proteins and by increased motility. This may represent an in vitro model of a step in the metastatic process occurring subsequent to invasion. The paclitaxel-resistant variants, MDA-MB-435S-F/Taxol-10p and MDA-MB-435S-F/Taxol-10p4p were resistant to paclitaxel, vincristine and docetaxel, but not to doxorubicin, carboplatin, etoposide or 5-fluorouracil. The doxorubicin-selected variants MDA-MB-435S-F/Adr-10p and MDA-MB-435S-F/Adr-10p10p, in contrast, exhibited only small increases in resistance to doxorubicin, although they were slightly resistant to VP-16 and docetaxel, and exhibited increased sensitivity to paclitaxel, carboplatin and 5-fluorouracil.
Collapse
Affiliation(s)
- S A Glynn
- National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
| | | | | | | | | | | | | |
Collapse
|
40
|
Piskareva OA, Barron N, Clynes M, Shmatchenko VV. In vivo cytoplasmic localization of the p40 protein of the L1 transposable element of human genome. DOKL BIOCHEM BIOPHYS 2004; 395:118-9. [PMID: 15253567 DOI: 10.1023/b:dobi.0000025561.05664.c1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- O A Piskareva
- Skryabin Institute of Biochemistry and Physiology of Microorganisms, Russian Academy of Sciences, pr Nauki 5, Pushchino, Moscow oblast, 142292 Russia
| | | | | | | |
Collapse
|
41
|
O' Leary M, O' Connor R, Roy S, Ballot J, Ooi W, Fennelly D, Sheehan L, Collins C, Clynes M, Crown J. Phase I trial of the multi-drug resistance (MDR) Protein-1 (MRP-1) modulating agent sulindac (S) plus epirubicin (E) in patients (pts) with advanced cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. O' Leary
- St.Vincent's University Hospital, Dublin 4, Ireland; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
| | - R. O' Connor
- St.Vincent's University Hospital, Dublin 4, Ireland; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
| | - S. Roy
- St.Vincent's University Hospital, Dublin 4, Ireland; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
| | - J. Ballot
- St.Vincent's University Hospital, Dublin 4, Ireland; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
| | - W. Ooi
- St.Vincent's University Hospital, Dublin 4, Ireland; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
| | - D. Fennelly
- St.Vincent's University Hospital, Dublin 4, Ireland; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
| | - L. Sheehan
- St.Vincent's University Hospital, Dublin 4, Ireland; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
| | - C. Collins
- St.Vincent's University Hospital, Dublin 4, Ireland; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
| | - M. Clynes
- St.Vincent's University Hospital, Dublin 4, Ireland; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
| | - J. Crown
- St.Vincent's University Hospital, Dublin 4, Ireland; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
| |
Collapse
|
42
|
Abstract
BACKGROUND Cell replacement therapies have been proposed as possible alternatives to the current treatments for controlling blood glucose in insulin-dependent diabetes. Beta cells, however, often lose their glucose-stimulated insulin secretion (GSIS) when maintained for prolonged periods in culture. For beta cell lines to be considered as a suitable source of transplantable tissue, it is essential that their GSIS is maintained. This study aimed to investigate cellular events involved in this loss of GSIS, to enable future optimization and enhancement of this response. METHODS GSIS was investigated in low and high-passage murine insulinoma MIN-6 cells (using in vitro static procedures) and assessing levels of secreted (pro)insulin by enzyme-linked immunosorbent assays. Expression of relevant islet gene transcripts, including insulin, glucagon, somatostatin, and pancreatic polypeptide, was investigated by RT-PCR analysis. RESULTS At low-passage, MIN-6 cells produced an approximately four- to fivefold increase in (pro)insulin secretion in response to 26.7 mmol/L glucose compared to 3.3 mmol/L glucose; at high passage, this response was lost. Expression of glucagon and somatostatin mRNAs were down-regulated with increased passage, while levels of insulin and pancreatic polypeptide mRNAs were apparently unchanged. CONCLUSION The maintenance of insulin mRNA levels in high-passage MIN-6 cells with down-regulation of glucagon (stimulates insulin secretion) and somatostatin (inhibits insulin secretion) gene transcript levels suggests that these cells have not lost their ability to maintain insulin production, but that the loss of glucose responsiveness may be due to a general effect on regulated secretion. Further studies investigating the regulated secretory pathway in these cells may further explain the mechanistic changes occurring with passaging of beta cells.
Collapse
Affiliation(s)
- L O'Driscoll
- National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland.
| | | | | |
Collapse
|
43
|
Abstract
BACKGROUND Although it has been established that formation and functional differentiation of the pancreas from embryonic endoderm is associated with activation/inactivation of many genes controlled by specific sets of transcription factors, the role and activation sequence of individual transcription factors has not yet been fully elucidated. This study sought to differentiate a murine teratocarcinoma cell line, F9, to endodermal-like cells and, subsequently; to investigate the effects of regulated expression of transcription factors in pancreas development. METHODS Following differentiation using retinoic acid and db cAMP (RAC), resulting F9 cells (F9-RAC) were transfected with cDNAs for PDX-1, ngn3, beta 2/NeuroD (beta 2), and Nkx2.2, singly or in combination. Expression of these transcription factors was investigated using RT-PCR and immunofluorescence techniques. RT-PCR analysis was used to assess the subsequent effects of expression of these factors on endogenous genes related to pancreas development. RESULTS Regulated differentiation of F9 cells generated endodermal-like cell types. Following transfection, PDX-1, ngn3, beta 2, and Nkx2.2 were expressed in F9-RAC cells, with their proteins localized mainly in cellular nuclei. Expression of these factors apparently did not affect the endogenous expression of preproinsulin, PDX-1, beta 2, Isl1, Pax4, Pax6, Sonic hedgehog, and Indian hedgehog. CONCLUSION This study describes the successful transient expression of transcription factors related to pancreas development, following directed differentiation of F9 cells to endoderm-like cells, and shows that treatment of F9 cells with a combination of RAC causes up-regulation of genes relevant to pancreatic development. The lack of further effect of regulated transcription factor expression on these genes may suggest that parietal endoderm- like cells derived from F9 cells is not the optimal lineage from which to develop beta cells. It may be useful to include F9-derived visceral endoderm in future studies.
Collapse
Affiliation(s)
- L O'Driscoll
- National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland.
| | | | | |
Collapse
|
44
|
O'Driscoll L, Cronin D, Kennedy SM, Purcell R, Linehan R, Glynn S, Larkin A, Scanlon K, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Clynes M. Expression and prognostic relevance of Mcl-1 in breast cancer. Anticancer Res 2004; 24:473-82. [PMID: 15152946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
BACKGROUND Bcl-2, an anti-apoptotic protein, is frequently associated with favourable prognosis in breast cancer. The potential role of mcl-1, another bcl-2 family member, in breast cancer has not yet been defined. PATIENTS AND METHODS This study examined the expression of mcl-1 and bcl-2 in 170 cases of invasive primary breast carcinoma, using reverse-transcriptase polymerase chain reaction and immunohistochemical analyses. RESULTS Expression of bcl-2 mRNA and protein were found to be favourably associated with outcome for patients, supporting a prognostic role for bcl-2 in breast cancer, whereas mcl-1 expression, at the mRNA or protein level, did not correlate with tumour size, grade, lymph node or ER status, age of patient at diagnosis, or disease outcome. CONCLUSION As these analyses of mcl-1 expression may have co-detected mcl-1(S/deltaTM) (a more recently identified, shorter variant, that may be pro-apoptotic) with the anti-apoptotic wild-type of mcl-1, it is possible that future studies may indicate some significant clinical correlations if the isoforms can be independently investigated.
Collapse
Affiliation(s)
- L O'Driscoll
- National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Keenan J, Liang Y, Clynes M. Two-deoxyglucose as an anti-metabolite in human carcinoma cell line RPMI-2650 and drug-resistant variants. Anticancer Res 2004; 24:433-40. [PMID: 15152941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
The accumulation of 2-deoxyglucose (2-DG), a glycolytic inhibitor, was investigated in a human nasal carcinoma cell line, RPMI-2650 and two of its drug-resistant variants (selected with taxol and melphalan) to assess manipulation of glycolytic potential as a selective means of reducing resistance. 2-DG uptake was increased 3-fold and 9.9-fold in taxol- and melphalan-resistant variants of RPMI-2650, respectively. Two of the principal factors associated with increased 2-DG uptake, namely glucose transporters and hexokinase activity, were increased in the resistant variants. Other changes in glucose metabolism that may affect 2-DG as an antimetabolite were observed, including increases in glucose-6-phosphate dehydrogenase of 10-fold and 100-fold for taxol- and melphalan-resistant variants, respectively, suggesting higher pentose phosphate activity; increased glutamine utilisation and greater sensitivity to iodoacetic acid-induced depletion of ATP levels in the parent relative to the resistant variants.
Collapse
Affiliation(s)
- J Keenan
- National Cell and Tissue Culture Centre/National Institute of Cellular Biology, Dublin City University, Glasnevin, Dublin 9, Ireland.
| | | | | |
Collapse
|
46
|
Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R, Clynes M. Prognostic importance of survivin in breast cancer. Br J Cancer 2003; 88:1077-83. [PMID: 12671708 PMCID: PMC2376388 DOI: 10.1038/sj.bjc.6600776] [Citation(s) in RCA: 185] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
Survivin is a member of the inhibitor of apoptosis (IAP) family, and is also involved in the regulation of cell division. Survivin is widely expressed in foetal tissues and in human cancers, but generally not in normal adult tissue. This study examined the expression of surviving protein in a series of 293 cases of invasive primary breast carcinoma. Survivin immunoreactivity was assessed using two different polyclonal antibodies, and evaluated semiquantitatively according to the percentage of cells demonstrating distinct nuclear and/or diffuse cytoplasmic staining. Overall, 60% of tumours were positive for survivin: 31% demonstrated nuclear staining only, 13% cytoplasmic only, and 16% of tumour cells demonstrated both nuclear and cytoplasmic staining. Statistical analysis revealed that survivin expression was independent of patient's age, tumour size, histological grade, nodal status, and oestrogen receptor status. In multivariate analysis, nuclear survivin expression was a significant independent prognostic indicator of favourable outcome both in relapse-free and overall survival (P<0.001 and P=0.01, respectively). In conclusion, our results show that survivin is frequently overexpressed in primary breast cancer. Nuclear expression is most common and is an independent prognostic indicator of good prognosis.
Collapse
Affiliation(s)
- S M Kennedy
- Department of Pathology and Research Foundation, Royal Eye and Ear Hospital, Dublin, Ireland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
Survivin, an inhibitor of apoptosis (IAP) containing one baculovirus IAP repeat (BIR) domain, has been reported to be capable of regulating both cellular proliferation and apoptotic cell death. Survivin splice variants, survivin-DeltaEx3 and survivin-2B, have apparently retained and lost anti-apoptotic potential, respectively. As survivin was first discovered due to its high homology with effector cell protease receptor (EPR-1), a protein involved in blood coagulation, it has been suggested (but not proven) that EPR-1 may act as a natural anti-sense to survivin in cells. Survivin homologs have been found in non-human species. Survivin expression has been described during embryonic development and in adult cancerous tissues, with greatly reduced expression in adult normal differentiated tissues, particularly if their proliferation index is low. Survivin has been defined as a universal tumor antigen and as the fourth most significant transcriptosome expressed in human tumors. Although survivin is usually located in the cell cytoplasmic region and associated with poor prognosis in cancer, nuclear localisation, indicative of favorable prognosis, has also been reported. Survivin expression has also been reported in a number of proliferating normal adult tissues. Extensive research has been conducted, aimed at increasing our understanding of survivin, by determining its sub-cellular structure and location, mechanism(s) of action and control of expression. While much important information on this molecule has been accumulated, there are still many areas of controversy or limited information. Further research may enable exploitation of survivin overexpression in cancer compared to normal tissues, making survivin a potentially attractive target for cancer therapeutics.
Collapse
Affiliation(s)
- L O'Driscoll
- National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
| | | | | |
Collapse
|
48
|
Moran E, O'Keeffe M, O'Connor R, Larkin AM, Murphy P, Clynes M. Methods for generation of monoclonal antibodies to the very small drug hapten, 5-benzimidazolecarboxylic acid. J Immunol Methods 2002; 271:65-75. [PMID: 12445730 DOI: 10.1016/s0022-1759(02)00340-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Drug-specific monoclonal antibodies (MAbs) were produced against the very small drug hapten (162.15 Da), 5-benzimidazolecarboxylic acid, an analogue of 2-(4-Thiazolyl)benzimidazole (TBZ) but lacking the thiol group. TBZ is widely used as a broad-spectrum anthelmintic in various animal species and humans and also as a food preservative and agricultural fungicide. The anti-5-benzimidazolecarboxylic acid antibodies produced have potential use for extraction and/or detection of protein-bound residue forms of TBZ. Three in vivo immunisation regimes (with combinations of two related small drug haptens and two different adjuvants/carrier molecules) and an in vitro immunisation procedure using a combination of three related unconjugated small drug haptens were investigated. Specificity for the hapten immunogen/s was initially determined using two different ELISA procedures. BIACORE analysis, in conjunction with drug binding inhibition studies, was used to confirm the specificity of a small number of selected clones. In vivo immunisation with a drug molecule conjugated to a lipopeptide/T-cell epitope, which acts both as a carrier molecule and an adjuvant was the most useful of the methods tested for the production of specific MAbs to a typically very small hapten with low immunogenic properties.
Collapse
Affiliation(s)
- E Moran
- National Cell and Tissue Culture Centre, Dublin City University, Glasnevin, Ireland.
| | | | | | | | | | | |
Collapse
|
49
|
Touhey S, O'Connor R, Plunkett S, Maguire A, Clynes M. Structure-activity relationship of indomethacin analogues for MRP-1, COX-1 and COX-2 inhibition. identification of novel chemotherapeutic drug resistance modulators. Eur J Cancer 2002; 38:1661-70. [PMID: 12142058 DOI: 10.1016/s0959-8049(02)00128-4] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
We report the screening of analogues of indomethacin to investigate the structure-activity relationship (SAR) of indomethacin-mediated multidrug resistance associated protein-1 (MRP-1) inhibition. By examining the activities of compounds with minor variations of the parent structure, we were able to separate MRP-1, glutathione-S-transferase (GST), cyclooxygenase (COX)-1 and COX-2 inhibitory activities. Combination cytotoxicity assays were utilised to identify agents which possess synergistic potential in MRP-1-expressing cell lines. MRP-1 Inside Out Vesicles (IOVs) were utilised to demonstrate the ability of the indomethacin analogues to inhibit the pump directly. Most of the indomethacin analogues active as MRP-1 inhibitors were poor GST inhibitors when compared with the GST-inhibitory activity of indomethacin. Two of the MRP-1 inhibitory analogues were found to have no COX-1 inhibitory activity and low COX-2 inhibitory activity, suggesting potentially reduced clinical toxicity. One MRP-1 inhibitory indomethacin analogue was also found to have low COX-1 inhibitory activity, but significant COX-2 inhibitory activity, making this analogue again interesting in terms of low potential toxicity, but with the possibility of direct inhibitory effects on tumour growth.
Collapse
Affiliation(s)
- S Touhey
- The National Cell and Tissue Culture Centre, Dublin City University, Glasneuin, 9, Dublin, Ireland
| | | | | | | | | |
Collapse
|
50
|
Meleady P, Clynes M. Bromodeoxyuridine induces integrin expression at transcriptional (alpha2 subunit) and post-transcriptional (beta1 subunit) levels, and alters the adhesive properties of two human lung tumour cell lines. Cell Commun Adhes 2002; 8:45-59. [PMID: 11775028 DOI: 10.3109/15419060109080706] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Integrins are a family of transmembrane glycoproteins that participate in a wide range of cellular events including proliferation, apoptosis and differentiation. Little is known about the mechanisms that control integrin subunit expression in epithelial cells, especially during lung cell differentiation. We have examined the effect of the differentiation-modulating agent, 5-bromo-2'-deoxyuridine (BrdU), on integrin expression in 2 human lung carcinoma cell lines, DLKP and A549. Treatment of both DLKP and A549 with 10 microM BrdU for 7 days resulted in increased expression of alpha2 and beta1 integrin subunit protein expression. Northern blot and RT-PCR analyses revealed progressively increasing levels of the alpha2 mRNA transcripts following BrdU treatment up to 21 days in both cell lines. However, no increase in beta1 integrin mRNA levels was observed in either cell, suggesting post-transcriptional regulation by BrdU. Treatment of HL-60, a leukaemic cell line, with BrdU up to 21 days resulted in no change in alpha2 or beta1 integrin subunit levels at either protein or mRNA levels suggesting that the change seen in the lung cell lines may be epithelial cell lineage-specific. BrdU has also been found to alter the adhesive properties of A549 and DLKP cells. Treated cells were found to adhere significantly faster to collagen type IV and laminin compared to untreated cells. The results presented here suggest that DLKP (and A549) may be useful cellular models to investigate the role of the alpha2beta1 integrin in lung epithelial cell differentiation.
Collapse
Affiliation(s)
- P Meleady
- National Cell and Tissue Culture Centre, Dublin City University, Glasnevin, Dublin, Ireland.
| | | |
Collapse
|